A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis

被引:7
作者
Saadi, Mohammed [1 ]
Yu, Christine [1 ]
Othman, Mohamed O. [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Med, Div Gastroenterol & Hepatol,Paul L Foster Sch Med, El Paso, TX USA
关键词
Cholangiocarcinoma; Cholestasis; Liver transplantation; Primary sclerosing cholangitis;
D O I
10.14218/JCTH.2013.00021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disease that often leads to the development of cirrhosis. Complications of PSC include pruritus, fatigue, vitamin deficiencies, metabolic bone disease, dominant biliary strictures, gallstones, and hepatobiliary malignancies, most commonly cholangiocarcinoma (CCA). Despite the presumed autoimmune etiology of PSC, a clear benefit from immunosuppressive agents has not yet been established, and their use is limited by their side effects. Endoscopy is required in evaluation of biliary strictures in PSC to rule out the possibility of CCA. Liver transplantation is currently the only life-extending therapy for patients with end-stage disease. However, disease recurrence can be a source of morbidity and mortality as transplanted patients survive longer. Further studies are needed to develop an optimal therapeutic strategy for patients with PSC to decrease the incidence of complications of the disease, to decrease the need for transplantation, and to extend life expectancy. (C) 2014 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 120 条
[1]   Sclerosing cholangitis: A focus on secondary causes [J].
Abdalian, Rupert ;
Heathcote, E. Jenny .
HEPATOLOGY, 2006, 44 (05) :1063-1074
[2]  
Angulo P, 2000, AM J GASTROENTEROL, V95, P2333
[3]   Pirfenidone in the treatment of primary sclerosing cholangitis [J].
Angulo, P ;
MacCarty, RL ;
Sylvestre, PB ;
Jorgensen, RA ;
Wiesner, RH ;
LaRusso, NA ;
Lindor, KD .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (01) :157-161
[4]   Serum autoantibodies in patients with primary sclerosing cholangitis [J].
Angulo, P ;
Peter, JB ;
Gershwin, ME ;
DeSotel, CK ;
Shoenfeld, Y ;
Ahmed, AEE ;
Lindor, KD .
JOURNAL OF HEPATOLOGY, 2000, 32 (02) :182-187
[5]   Silymarin in the treatment of patients with primary sclerosing cholangitis: An open-label pilot study [J].
Angulo, Paul ;
Jorgensen, Roberta A. ;
Kowdley, Kris V. ;
Lindor, Keith D. .
DIGESTIVE DISEASES AND SCIENCES, 2008, 53 (06) :1716-1720
[6]   Hepatic and extrahepatic malignancies in primary sclerosing cholangitis [J].
Bergquist, A ;
Ekbom, A ;
Olsson, R ;
Kornfeldt, D ;
Lööf, L ;
Danielsson, Å ;
Hultcrantz, R ;
Lindgren, S ;
Prytz, H ;
Sandberg-Gertzén, H ;
Almer, S ;
Granath, F ;
Broomé, U .
JOURNAL OF HEPATOLOGY, 2002, 36 (03) :321-327
[7]   URSODEOXYCHOLIC ACID FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - A PLACEBO-CONTROLLED TRIAL [J].
BEUERS, U ;
SPENGLER, U ;
KRUIS, W ;
AYDEMIR, U ;
WIEBECKE, B ;
HELDWEIN, W ;
WEINZIERL, M ;
PAPE, GR ;
SAUERBRUCH, T ;
PAUMGARTNER, G .
HEPATOLOGY, 1992, 16 (03) :707-714
[8]  
Bharucha AE, 2000, AM J GASTROENTEROL, V95, P2338
[9]   Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis:: Analysis of the underlying mechanisms [J].
Biecker, E ;
De Gottardi, A ;
Neef, M ;
Unternährer, M ;
Schneider, V ;
Ledermann, M ;
Sägesser, H ;
Shaw, S ;
Reichen, J .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :952-961
[10]   Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis [J].
Björnsson, E ;
Cederborg, A ;
Åkvist, A ;
Simren, M ;
Stotzer, PO ;
Bjarnason, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2005, 40 (09) :1090-1094